5 not yet recruiting, 4 completed, 4 unknown, 3 recruiting. 9 Not applicable, 3 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 9 | Not yet recruiting 3, Recruiting 3, Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Chronic Kidney Disease Stage 4: new trials by email Literature Review of Chronic Kidney Disease Stage 4 trials Research Report on Chronic Kidney Disease Stage 4
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Agenda-Setting for Kidney Disease Trial Chronic Kidney Disease Structured Agenda-Setting Tool - Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5 | Not applicable | Not yet recruiting | Dartmouth-Hitchcock Medical Center | 108 | 2026-09-01 | 2025-06-24 |
| The Agenda-Setting for Kidney Disease Open Pilot Trial Chronic Kidney Disease Structured Agenda-Setting Tool - Chronic Kidney Disease Stage 4 | Not applicable | Recruiting | Dartmouth-Hitchcock Medical Center | 30 | 2026-05-19 | 2026-07-23 |
| Kidney Transplant Improvement Through New Exercise Training to Increase Capacity Exercise Rehabilitation Program with Physical Activity Tracker, Active control - Chronic Kidney Disease 5D, Chronic Kidney Disease Stage 5 | Not applicable | Recruiting | University of Pennsylvania | 60 | 2026-03-24 | 2026-05-06 |
| Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD） Henagliflozin 5 mg Group, Henagliflozin 10 mg Group, Conventional therapy group - Chronic Kidney Disease Stage 4 | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 429 | 2025-07-10 | 2025-06-18 |
| Clinical Effectiveness of MyNutriKidney® Counseling, Renal Diet App, Printed Nutrition Pamphlet - Chronic Kidney Disease Stage 3, Chronic Kidney Disease | Not applicable | Not yet recruiting | Universiti Putra Malaysia | 200 | 2025-07-01 | 2025-05-04 |
| Improving Medication Safety for Kidney Disease With a Digital Drug Dosing Tool in Nova Scotia Community Pharmacy Practice. Electronic Drug Dosing and Decision Support Kidney (eDoseCKD) Tool - Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5 | Not yet recruiting | Nova Scotia Health Authority | 125 | 2025-06-01 | 2025-02-11 | |
| A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced CKD and Clinicians "CKD Jumpstart- Tips" priming intervention - Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5 | Not applicable | Recruiting | The University of Hong Kong | 280 | 2025-02-04 | 2026-09-08 |
| Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease Fluorescein angiography - Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B | Not applicable | Not yet recruiting | Saint-Joseph University | 35 | 2025-01-07 | 2025-01-07 |
| Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease Sulforaphane (Avmacol Extra Strength), Placebo - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Phase 2 | Completed | University of Rochester | 96 | 2023-05-03 | 2026-05-18 |
| KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients. KEFPEP®, Placebo - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Not applicable | Completed | National Chung Hsing University | 165 | 2023-02-03 | 2026-09-01 |
| The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2 | Unknown | Far Eastern Memorial Hospital | 81108 | 2021-03-03 | 2022-05-10 | |
| Desidustat in the Treatment of Anemia in CKD Desidustat Oral Tablet, Darbepoetin Alfa - Chronic Kidney Disease Stage 3, Anemia | Phase 3 | Completed | Zydus Lifesciences Limited | 588 | 2019-07-20 | 2021-11-24 |
| Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients Vitamin K2 (menaquinone-7; 360-mcg/d), Placebo-Control - Cardiovascular Diseases, Chronic Kidney Disease Stage 3 | Not applicable | Unknown | Augusta University | 60 | 2017-09-13 | 2019-11-20 |
| A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control Placebo, Sotagliflozin - Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4 | Phase 3 | Completed | Lexicon Pharmaceuticals | 277 | 2017-08-16 | 2021-06-25 |
| Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease Left atrial appendage occlusion - Blood Coagulation Disorders, Atrial Fibrillation | Not applicable | Terminated | University of Magdeburg | 14 | 2014-01-01 | 2018-11-21 |
| Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients Aspirin - Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3 | Phase 3 | Unknown | Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales | 97 | 2010-05-01 | 2012-10-18 |
| Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Unknown | National University of Singapore | 400 | 2015-04-15 |
Renal Insufficiency, Chronic (17) · Patient Participation (2) · Acute Kidney Injury (1) · Anemia (1) · Atrial Fibrillation (1) · Blood Coagulation Disorders (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Communication (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Disease Progression (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Metabolic Syndrome (1)
Disease Attributes (17) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Urogenital Diseases (17) · Urologic Diseases (17) · Chronic Disease (16) · Kidney Diseases (16) · Renal Insufficiency (16) · Nutritional and Metabolic Diseases (4) · Behavior (3) · Glucose Metabolism Disorders (3) · Hematologic Diseases (3)
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · Aspirin (1) · Counseling (1) · Darbepoetin alfa (1) · Equipment and Supplies (1) · Fluorescein Angiography (1) · Left Atrial Appendage Closure (1) · Population Groups (1) · Vitamin K 2 (1) · Walking (1) · desidustat (1) · henagliflozin (1) · menaquinone 7 (1) · sulforaphane (1)
Dartmouth-Hitchcock Medical Center (2) · Augusta University (1) · Far Eastern Memorial Hospital (1) · First Affiliated Hospital of Wannan Medical College (1) · Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales (1) · Lexicon Pharmaceuticals (1) · National Chung Hsing University (1) · National University of Singapore (1) · Nova Scotia Health Authority (1) · Saint-Joseph University (1) · The University of Hong Kong (1) · Universiti Putra Malaysia (1) · University of Magdeburg (1) · University of Pennsylvania (1) · University of Rochester (1)
United States (6) · Germany (2) · Spain (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Colombia (1) · Hong Kong (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Lebanon (1) · Malaysia (1) · Mexico (1)
DrDeven Parmar, MD (1) · Jacqueline KY Yuen, Dr (1) · Norman K Pollock, PhD (1) · Sarah Schrauben, MD, MSCE (1) · Suman Wason, MD (1)
PMID 25959301, PMID 29943364, PMID 32478665, PMID 32795256, PMID 33066603, PMID 34338408, PMID 35224730, PMID 36005278, PMID 38222892, PMID 38770818, PMID 39472832
K01DK139400 (2), 2016 (1), R01DK128677 (1), R01DK144325 (1)